Amendments to the Specification

Please amend the specification by replacing paragraph [0035] of the present specification with the following amended paragraph:

[0035] The proteins synthesized and/or secreted by the tumors may be, in a particularly preferred embodiment, the proteins listed in table I shown below. Thus, the substance employed for detecting and/or for diagnosing tumor-associated disorders may be for example an antibody which is directed against these proteins and is employed in a detection method known to the skilled worker, such as, for example, ELISA (enzyme-linked immuno sorbent assay). In such so-called immunoassays, the specific antibody directed against the antigen to be determined (or in the case of antibody determinations homologous testantigens) is bound to a support substance (e.g. cellulose, polystyrene) on which immune complexes form after incubation with the sample. In a subsequent step, a labeled antibody is added to these immune complexes. It is possible, by adding a homogeneous substrate to the reaction mixture, to visualize the immune complex-bound enzyme-substrate complexes and estimate the antigen concentration in the sample via a photometric determination of the immune complex-bound marker enzymes by comparison with standards of known enzymic activity. Further substances which can be used for the diagnostic detection are, for example, so-called oligonucleotides which are suitable, with the aid of the so-called polymerase chain reaction (PCR), via a molecular genetic method in which there is selective amplification of particular DNA segments, for achieving quantitative detection of the investigated proteins. Further methods allowing a known target protein to be detected quantitatively or qualitatively are familiar to the skilled worker. Active ingredients which can be used for at least partial inhibition of these proteins are likewise known to the skilled worker. Thus, for example, so-called antisense sequences can be used as active ingredient. It is

additionally possible to use genetically modified mutants of these proteins according to the invention as active ingredient, e.g. so-called deficient mutants in which the enzymatic activity has been eliminated. Protein NM_018946, Sialic acid synthase, identified by accession number gi 12056473 and shown in row 6 of Table 1 corresponds to SEQ ID NO: 1. Protein AB_001517, KNP-I beta, identified by accession number gi_2250701 and shown in row 16 of Table 1 corresponds to SEQ ID NO: 2.